Tag: Prescription Drugs

Displaying 101 - 120 of 146 results.

The Federal Trade Commission today announced its decision to challenge the terms of Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, a deal that would have led to competitive problems in the markets for 13 generic drug products. In allowing the deal to proceed...
U.S. District Court Judge Colleen Kollar-Kotelly yesterday entered a final order settling the Federal Trade Commission’s charges that drug company Warner Chilcott’s agreement with Barr Laboratories unlawfully delayed entry of Barr’s generic version of Warner Chilcott’s Ovcon birth control pill.
Protecting competition for the sale of prescription drug Ovcon, the Federal Trade Commission today announced that it has agreed to settle its complaint against Warner Chilcott, which manufactures the branded version of the drug. The settlement will result in lower prices for women who use the...
The consent order settles charges that Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion would have eliminated current or future competition between Barr and Pliva in certain markets for generic pharmaceuticals treating depression, high...
The Federal Trade Commission today announced its decision to challenge Barr Pharmaceutical, Inc.’s proposed acquisition of Pliva d.d for approximately $2.5 billion. The FTC’s complaint alleges that the acquisition as originally structured would have eliminated current or future competition between...
The Federal Trade Commission’s Bureau of Competition today issued a summary of agreements filed with the Commission in fiscal year 2005 (ending September 30, 2005) by generic and branded drug manufacturers. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires drug...
Commission approval of final consent order: Following a public comment period, the Commission has approved the issuance of a final consent order in the matter concerning Allergan, Inc.’s acquisition of Inamed Corporation. The vote to approve the final order was 4-0, with Commissioner J. Thomas...
The Federal Trade Commission today announced its intention to conduct a study of the use, and likely short- and long-term competitive effects, of authorized generics in the prescription drug marketplace. An authorized generic is chemically identical to a particular brand-name drug, but the brand-...
Botox marketer Allergan, Inc., and the Inamed Corporation will divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle Federal Trade Commission charges that Allergan’s $3.2 billion purchase of Inamed would violate federal antitrust laws. The FTC alleges that...
Commission authorization of the filing of staff comment:The Commission has authorized the staffs of the Bureau of Consumer Protection, Bureau of Economics, and Office of Policy Planning to file a letter with the New Jersey Supreme Court Committee on Attorney Advertising regarding Proposed...
Under a consent agreement announced today, the Federal Trade Commission will allow Teva Pharmaceutical Industries Ltd.’s (Teva) proposed acquisition of IVAX Corporation (IVAX), provided the companies sell the rights and assets needed to manufacture and/or market 15 generic pharmaceutical products.
The Commission settled with Barr Laboratories concluding its federal court action challenging an agreement between Warner Chilcott and Barr in which, the Commission alleged, Barr agreed not to sell a lower-priced generic substitute of Warner Chilcott’s branded Ovcon 35, an oral...
The Federal Trade Commission today filed a complaint in federal district court seeking to put an end to an agreement between drug manufacturers Galen Chemicals Ltd. (now known as Warner Chilcott) and Barr Laboratories (Barr) that is denying consumers the choice of a lower-priced generic version of...
To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release...
Preserving competition in U.S. markets for three generic pharmaceuticals, the Federal Trade Commission today approved Novartis AG’s (Novartis) $1.72 billion acquisition of Eon Labs, Inc. (Eon), provided Novartis divests three overlapping drugs to Amide Pharmaceutical, Inc. (Amide).
The Federal Trade Commission today filed a petition with the Court of Appeals for the Eleventh Circuit, in Atlanta, Georgia, requesting that the Court vacate its March 8, 2005 decision in the matter of FTC v. Schering-Plough Corporation, No. 04-10688, and re-hear the case en banc.
Commission response to Food and Drug Administration citizen petition: The Commission has authorized the submission of a response to the U.S. Food and Drug Administration (FDA) regarding a citizen petition filed with the FDA by IVAX Pharmaceuticals, Inc. (IVAX) on January 5, 2005. The petition...
Commission authorization of the staff to file amicus brief: The Commission has authorized the staff to file a brief as amicus curiae in Teva Pharmaceuticals USA, Inc. v. Pfizer, Inc., Case No. 04-1186 (Fed. Cir.) in support of Teva’s petition for rehearing or rehearing en banc. The case, which was...
Commission approval of final consent order: Following a public comment period, the Commission has approved a final consent order in the matter concerning Genzyme Corporation and ILEX Oncology, Inc. The Commission vote approving the final consent order was 4-0-1, with Commissioner Pamela Jones...
A consent order allowed Genzyme’s acquisition of ILEX Oncology, Inc., but requires the companies to divest certain assets in the market for solid organ transplant acute therapy drugs. Specifically, Genzyme is required to divest all contractual rights related to ILEX’s Campath®, an...

Pages